Studienzentrum Dr. Faulmann GbR
- Address
- lock Available on a paid plan
Studienzentrum Dr. Faulmann GbR - Infectious Disease and Nephrology Research
Studienzentrum Dr. Faulmann GbR is a specialized clinical research center conducting Phase III trials across diverse therapeutic areas. The center demonstrates particular expertise in vaccine research and chronic disease management, with a focus on vulnerable adult populations and innovative therapeutic combinations.
- Respiratory syncytial virus (RSV) vaccine studies, including long-term immunogenicity and revaccination protocols in older adults
- Chronic kidney disease research with emphasis on proteinuria management and renal function preservation
- Novel fixed-dose combination therapies evaluating dual-mechanism approaches for complex chronic conditions
The research center's capabilities span from extension and crossover vaccination studies examining immune responses over multiple seasons to sophisticated chronic kidney disease trials evaluating combination pharmacotherapies. Their work with RSVPreF3 OA vaccine in adults 60 years and older, alongside studies of zibotentan combined with dapagliflozin for high proteinuria, reflects a commitment to addressing critical unmet needs in both infectious disease prevention and metabolic-renal pathology management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Studienzentrum Dr. Faulmann GbR
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pragmatic Study Evaluating the Efficacy of Once-Weekly Insulin Icodec Versus Daily Basal Insulin Analogues in Insulin-Naïve Adults with Type 2 Diabetes | Novo Nordisk A/S | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2024-04-04 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.